Iron addiction: A novel therapeutic target in ovarian cancer

[1]  N. Nagarajan,et al.  In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells , 2016, The Journal of pathology.

[2]  F. Torti,et al.  Iron and cancer: recent insights , 2016, Annals of the New York Academy of Sciences.

[3]  B. Stockwell,et al.  Ferroptosis: Death by Lipid Peroxidation. , 2016, Trends in cell biology.

[4]  Xianquan Zhang,et al.  IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells , 2015, Cellular Oncology.

[5]  Nupur K. Das,et al.  Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. , 2015, Cancer cell.

[6]  N. Barker,et al.  Ovary and fimbrial stem cells: biology, niche and cancer origins , 2015, Nature Reviews Molecular Cell Biology.

[7]  J. George,et al.  Efficient molecular subtype classification of high‐grade serous ovarian cancer , 2015, The Journal of pathology.

[8]  L. Miller,et al.  Hepcidin regulation in prostate and its disruption in prostate cancer. , 2015, Cancer research.

[9]  D. Richardson,et al.  Novel Thiosemicarbazones Regulate the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway: Inhibition of Constitutive and Interleukin 6–Induced Activation by Iron Depletion , 2015, Molecular Pharmacology.

[10]  G. Ning,et al.  The PAX2‐null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium , 2014, The Journal of pathology.

[11]  C. Landen,et al.  Ovarian cancer stem cells: are they real and why are they important? , 2014, Gynecologic oncology.

[12]  J. Dietl.  Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube , 2014, Archives of Gynecology and Obstetrics.

[13]  Matthew E. Welsch,et al.  Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.

[14]  L. Miller,et al.  IRP2 regulates breast tumor growth. , 2014, Cancer research.

[15]  J. Mao,et al.  Quantifying chromogen intensity in immunohistochemistry via reciprocal intensity , 2013 .

[16]  R. Kurman.  Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[18]  F. Torti,et al.  Iron and cancer: more ore to be mined , 2013, Nature Reviews Cancer.

[19]  S. H. van der Burg,et al.  Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. , 2012, Current pharmaceutical design.

[20]  T. Ganz,et al.  Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. , 2012, Cell metabolism.

[21]  John Calvin Reed,et al.  Ironing Out Cell Death Mechanisms , 2012, Cell.

[22]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[23]  Suzy V. Torti,et al.  An iron regulatory gene signature predicts outcome in breast cancer. , 2011, Cancer research.

[24]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[25]  K. Griffith,et al.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. , 2011, Cancer research.

[26]  R. Drapkin,et al.  Modeling high-grade serous ovarian carcinogenesis from the fallopian tube , 2011, Proceedings of the National Academy of Sciences.

[27]  F. Torti,et al.  Ironing out cancer. , 2011, Cancer research.

[28]  R. Bast,et al.  Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer , 2010, Molecular Cancer Therapeutics.

[29]  E. Lengyel.  Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[30]  M. Willingham,et al.  Ferroportin and iron regulation in breast cancer progression and prognosis. , 2010, Science translational medicine.

[31]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[32]  R. Drapkin,et al.  Ovarian Cancer Pathogenesis: A Model in Evolution , 2009, Journal of oncology.

[33]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[34]  A. Ghanate,et al.  Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53‐Mediated Apoptosis and Acquiring a Stem‐Like Phenotype in Ovarian Cancer Cells , 2009, Stem cells.

[35]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[36]  J. Marks,et al.  Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells , 2009, Oncogene.

[37]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[38]  Guangchao Sui,et al.  PIASy-Mediated Sumoylation of Yin Yang 1 Depends on Their Interaction but Not the RING Finger , 2007, Molecular and Cellular Biology.

[39]  D. Haile,et al.  Functional consequences of ferroportin 1 mutations. , 2005, Blood cells, molecules & diseases.

[40]  V. Viprakasit,et al.  In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. , 2005, Blood.

[41]  Jing Wu,et al.  Iron-induced interleukin-6 gene expression: possible mediation through the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. , 2004, Toxicology.

[42]  William C Hahn,et al.  Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. , 2003, Cancer cell.

[43]  F. Torti,et al.  Regulation of ferritin genes and protein. , 2002, Blood.

[44]  K. Hatch,et al.  c-myc amplification in ovarian cancer. , 1990, Gynecologic oncology.

[45]  A. Malpica,et al.  Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. , 2014, International journal of clinical and experimental pathology.

[46]  B. Stockwell,et al.  The role of iron and reactive oxygen species in cell death. , 2014, Nature chemical biology.

[47]  D. Gershenson.  The life and times of low-grade serous carcinoma of the ovary. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.